The Business of Birth: Everleap’s Paramus Push and the Fertility Consolidation

PARAMUS, N.J. – November 11, 2026

The opening of a medical clinic in a suburban office park rarely signals a shift in global healthcare economics. Yet, the recent inauguration of a new reproductive care facility at 650 From Road in Paramus, New Jersey, is far more than a localized healthcare expansion. The ribbon-cutting by Everleap Fertility—a network formerly known as RMA New Jersey—serves as a high-visibility case study in the rapid corporatization, consolidation, and strategic deployment of reproductive medicine in the United States.

Everleap’s new full-service clinic, its twelfth location in the state, arrives at a critical inflection point for the fertility industry. Assisted reproductive technology (ART) is no longer a boutique medical niche; it is a booming, multi-billion-dollar global enterprise. As part of the IVI Institute, a reproductive medicine behemoth operating over 200 locations in 15 countries, the network’s expansion into Bergen County underscores how global capital and corporate strategy are reshaping the deeply personal journey of family building.

The Suburban Fertility Rush

At first glance, Bergen County does not look like a medical desert. The affluent North Jersey and New York City commuter corridor is already home to a dense concentration of highly regarded reproductive endocrinology providers. Institutions such as The Valley Hospital Fertility Center, Columbia University Fertility Center in Teaneck, and CCRM Fertility have long maintained a strong presence in the region. According to 2022 data from the Centers for Disease Control and Prevention, New Jersey’s 14 reporting fertility clinics collectively performed over 20,800 ART cycles in a single year, boasting a live-birth rate of 34.2 percent—slightly above the national average.

However, availability does not always equate to accessibility. The strategic placement of the Paramus clinic is a direct response to the logistical friction that plagues modern fertility patients. According to the IVI Institute Fertility Barometer, one in five U.S. women aged 19 to 49 report experiencing infertility, and nearly 38 percent of those surveyed cite waiting lists and the distance to clinics as primary barriers to pursuing treatment.

For suburban patients, the daily monitoring, blood draws, and ultrasounds required during an in vitro fertilization (IVF) cycle can turn a medical treatment into a logistical nightmare, particularly when core procedures are centralized at distant flagship locations. By embedding full-service capabilities—including IVF, intrauterine insemination (IUI), preimplantation genetic testing (PGT), and specialized care for LGBTQ+ individuals and oncology patients—directly into a major suburban retail and commuter hub, corporate networks are attempting to eliminate the "fertility commute."

“We’re thrilled to further expand Everleap Fertility’s presence across New Jersey and bring advanced fertility care closer to patients in Paramus,” said Dr. Marcy Maguire, Everleap Fertility New Jersey Clinical Director. “We are committed to increasing access to much-needed care in communities like Paramus across the state to help New Jerseyans realize their family-building dreams.”

The Corporatization of Conception

The transition from RMA New Jersey to Everleap Fertility is emblematic of a massive wave of private equity and institutional investment sweeping through reproductive healthcare. The rebranded entity was built on the legacies of RMA, Boston IVF, Conceptions, and several other leading North American practices. Today, it operates more than 65 locations and 25 IVF laboratories across the United States.

This consolidation under the IVI Institute umbrella fundamentally alters the business mechanics of fertility care. Historically, reproductive medicine was dominated by independent, physician-owned practices. Today, the model relies on immense economies of scale. A global parent company can standardize laboratory operations, bulk-purchase highly specialized medical equipment, and leverage vast, international datasets to refine clinical protocols.

For investors and corporate boards, this model promises efficiency and predictable revenue streams in a market where demand is virtually inelastic. For patients, the corporatization of conception offers a double-edged sword. On one hand, massive networks can invest heavily in cutting-edge embryology labs and proprietary research that small clinics simply cannot afford. On the other, industry watchdogs frequently raise concerns about the potential for corporate pressure to prioritize patient volume and standard operating procedures over highly personalized, bespoke medical care.

“It’s exciting to bring this practice to life alongside our lead physicians and work together to build a strong, collaborative team rooted in clinical excellence and compassionate patient care,” noted Dr. Maria Costantini-Ferrando, Everleap Fertility East Coast Regional Medical Director. “We have created an environment in Paramus where patients can feel supported, informed, and confident in their treatment, and we look forward to delivering the excellent patient experience and industry-leading outcomes that Everleap Fertility is known for.”

Navigating Mandates and Margins

The aggressive expansion into New Jersey is no geographic accident; it is heavily influenced by state-level healthcare policy. New Jersey is a pioneer in mandated fertility insurance coverage, requiring certain employers and insurers to cover the diagnosis and treatment of infertility.

While this mandate drastically lowers the barrier to entry for thousands of aspiring parents, it simultaneously supercharges market demand. This influx of insured patients is the hidden driver behind the very waiting lists that corporate networks cite as their reason for expansion. The mandate creates a reliable, insured consumer base, making the state an incredibly attractive market for well-capitalized fertility networks looking to scale.

Yet, even with robust insurance mandates, the margins and out-of-pocket costs remain formidable. Patients navigating the system often discover that while core procedures may be covered, ancillary services quickly add up. An IVF freeze-all cycle can easily carry a baseline price tag exceeding $15,000. Advanced interventions, such as PGT-A testing, often require additional thousands for biopsies and per-embryo analysis.

To bridge this gap, the industry is seeing a rise in specialized fertility financing and employer-sponsored benefit managers like Progyny, Maven, and Carrot Fertility. The Paramus clinic’s integration with these financial networks highlights how fertility care is increasingly operating at the intersection of advanced bioscience and complex financial engineering.

A Maturing Market Under the Microscope

As corporate fertility networks scale their operations, they are also operating under an increasingly watchful regulatory eye. Late last year, in December 2025, New Jersey implemented comprehensive state regulations for facilities storing human embryos and eggs. Prompted by catastrophic equipment failures in other states over the past decade, these new rules require strict licensure, rigorous equipment safety standards, emergency preparedness protocols, and enhanced quality management.

The regulatory tightening reflects a maturing industry. Fertility care is no longer the Wild West of medical science; it is a highly regulated, corporatized sector managing the most delicate and emotionally fraught biological assets imaginable. For companies operating under the IVI Institute, compliance with these stringent regulations requires the kind of capital and standardized infrastructure that large networks are uniquely positioned to provide.

The opening of the Paramus clinic is a testament to the new reality of reproductive medicine. It is a landscape where geographic convenience, corporate consolidation, insurance mandates, and state regulations intersect. As the industry continues to grow—with ART now accounting for roughly 2.6 percent of all births in the United States—the mechanics of power, profit, and patient care will remain inextricably linked, shaping the future of how families are built.